59/100BPfizer stock forecast 2026–2030
Analysts' average 12-month price target for Pfizer is 31.13, 5.9% above the current price of 29.39. Their targets range from 26.00 to 40.00.
Of the 13 firms that rated Pfizer in the past 12 months, 5 rate it buy or strong buy, 8 hold and 0 sell or strong sell (each firm at its latest rating): a Hold consensus.
Analysts' 1-year price targets range from 26.00 to 40.00, with an average of 31.13.
| Strong buy | 0 | |
| Buy | 5 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong sell | 0 |
12-month price target
| Highest target | 40.00 |
| Average target | 31.13 |
| Lowest target | 26.00 |
| Current price | 29.39 |
Pfizer price target history
Have analysts recently raised or lowered their Pfizer price target and rating?
How analysts rate Pfizer, month by month
5 of 13 firms rate it buy now, against 1 of 6 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Pfizer analyst upgrades, downgrades and price targets
The latest rating change came on 6 July 2026, when HSBC downgraded Pfizer from Buy to Hold. Its price target is 28.00, from 29.00. The most recent new target came from FBN Securities on 6 November 2026: 34.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 6 Nov 2026 | FBN Securities | — | 34.00 | — | 29.31 |
| 4 Nov 2026 | Argus Research David Toung | — | 40.00 | — | 30.79 |
| 8 Oct 2026 | Cantor Fitzgerald Carter Gould | Reiterated · Neutral | 27.00 → 28.00 | +3.7% | 28.00 |
| 6 Oct 2026 | Scotiabank | Reiterated · Sector Outperform | 33.00 | — | 27.31 |
| 10 Sept 2026 | HSBC | Reiterated · Hold | 28.00 → 30.00 | +7.1% | 27.78 |
| 7 Aug 2026 | Guggenheim | Reiterated · Buy | 35.00 → 31.00 | -11.4% | 26.20 |
| 6 Jul 2026 | HSBC | Downgraded · Buy → Hold | 29.00 → 28.00 | -3.4% | 24.32 |
| 10 Jun 2026 | RBC Capital | Upgraded · Underperform → Sector Perform | — | — | — |
| 27 May 2026 | UBS Michael Yee | — | 25.00 → 27.00 | +8.0% | 26.35 |
| 14 May 2026 | Wolfe Research Alexandria Hammond | — | 24.00 → 26.00 | +8.3% | 25.96 |
| 17 Mar 2026 | Morgan Stanley Terence Flynn | — | 28.00 → 27.00 | -3.6% | 27.06 |
| 9 Mar 2026 | BMO Capital Evan David Seigerman | — | 30.00 | — | 26.49 |
| 2 Mar 2026 | Argus Research | Upgraded · Hold → Buy | — | — | — |
| 24 Feb 2026 | RBC Capital Trung Huynh | — | 25.00 | — | 27.14 |
| 19 Feb 2026 | Barclays Emily Field | — | 25.00 | — | 26.86 |
| 12 Feb 2026 | Daiwa Narumi Nakagiri | — | 27.00 | — | 27.73 |
| 27 Jan 2026 | Cantor Fitzgerald | Reiterated · Neutral | 24.00 → 27.00 | +12.5% | 25.88 |
| 6 Jan 2026 | UBS | — | 28.00 → 25.00 | -10.7% | 25.43 |
| 17 Dec 2025 | Wolfe Research Alexandria Hammond | — | 24.00 | — | 25.53 |
| 12 Dec 2025 | Morgan Stanley | Reiterated · Equal Weight | 32.00 → 28.00 | -12.5% | 25.89 |
| 10 Dec 2025 | HSBC Rajesh Kumar | — | 29.00 | — | 25.33 |
| 24 Nov 2025 | Guggenheim | Reiterated · Buy | 35.00 | — | 25.17 |
Pfizer EPS and revenue estimates
Analysts expect Pfizer's EPS to grow 21.9% a year until 2028. Over the last 5 years it fell 3.5% a year, and over the last 3 years it fell 37.1%.
Analysts expect Pfizer's revenue to fall 4.1% a year until 2028. Over the last 5 years it grew 8.5% a year, and over the last 3 years it fell 14.8%.
Revenue
EPS
Does Pfizer beat earnings estimates?
On average, analysts' EPS estimate was 42.5% off the result, either way, and their revenue estimate 4.9%, over the last 12 quarters.
- EPS beats
- 98 / 136
- Revenue beats
- 94 / 118
- Average EPS surprise, last 12
- +42.5%
- Since
- January 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 3 Nov 2026 | 0.74 | 0.87 | +18.4% | 15.85B | 16.58B | +4.6% |
| Q2 FY2026 | 4 Aug 2026 | 0.68 | 0.77 | +12.9% | 14.40B | 15.03B | +4.4% |
| Q1 FY2026 | 5 May 2026 | 0.72 | 0.75 | +3.9% | 13.84B | 14.45B | +4.4% |
| Q4 FY2025 | 3 Feb 2026 | 0.57 | 0.66 | +16.4% | 16.85B | 17.56B | +4.2% |
| Q3 FY2025 | 4 Nov 2025 | 0.63 | 0.87 | +37.4% | 16.50B | 16.65B | +0.9% |
| Q2 FY2025 | 5 Aug 2025 | 0.58 | 0.78 | +34.5% | 13.56B | 14.65B | +8.1% |
| Q1 FY2025 | 29 Apr 2025 | 0.67 | 0.92 | +38.1% | 13.92B | 13.72B | -1.5% |
| Q4 FY2024 | 4 Feb 2025 | 0.47 | 0.63 | +33.6% | 17.35B | 17.76B | +2.4% |
| Q3 FY2024 | 29 Oct 2024 | 0.61 | 1.06 | +72.6% | 14.92B | 17.70B | +18.6% |
| Q2 FY2024 | 30 Jul 2024 | 0.46 | 0.60 | +31.0% | 12.96B | 13.28B | +2.5% |
| Q1 FY2024 | 1 May 2024 | 0.52 | 0.82 | +58.9% | 13.87B | 14.88B | +7.2% |
| Q4 FY2023 | 30 Jan 2024 | -0.19 | 0.10 | +152.6% | 14.25B | 14.25B | +0.0% |
Pfizer stock price 2026–2030: scenarios
If Pfizer's earnings keep growing at the -8.6% a year analysts expect to FY2028, it would earn about 2.06 a share in FY2030. At the P/E it has traded at over the last five years (9.2 to 76.7) that is 18.83 to 157.61 a share, or 56.64 at its average P/E of 27.6. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 3.01 | 27.56 | 82.89 | 230.67 |
| FY2027 | 2.92 | 26.71 | 80.32 | 223.51 |
| FY2028 | 2.46 | 22.56 | 67.86 | 188.84 |
| FY2029 (extrapolated) | 2.25 | 20.61 | 62.00 | 172.52 |
| FY2030 (extrapolated) | 2.06 | 18.83 | 56.64 | 157.61 |
Each year's EPS is the analysts' consensus to FY2028; the years after continue its -8.6% a year. Bear, base and bull apply the lowest, average and highest P/E of the last five fiscal year ends (9.2, 27.6, 76.7).
Is Pfizer stock undervalued or overvalued?
Pfizer's P/E of 41.6 is near the top of its 5-year range (6.8 to 75.5, median 14.8). Analysts expect faster growth than in recent years, which can explain part of the high P/E. Fair value is not a reliable guide for Pfizer: analysts expect EPS growth of 21.9% a year against -20.3% before, so its past P/E no longer describes it. Its forward P/E, on the consensus for FY2026, is 9.8.
- Price to earnings ratio (TTM)
- 41.58
- Five-year median P/E
- 14.78
- Five-year P/E range
- 6.8 – 75.5
- Forward P/E (FY2026)
- 9.77
- To the average target
- +5.9%
Most undervalued US stocks
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 99.090 | 195.10146Price 99.09244 | +96.9% | |
| 186.680 | 359.93270Price 186.68450 | +92.8% | |
| 213.670 | 405.66304Price 213.67507 | +89.9% | |
| 161.160 | 305.51157Price 161.16396 | +89.6% | |
| 42.225 | 79.0244Price 42.23157 | +87.1% | |
| 160.650 | 299.85225Price 160.65375 | +86.6% | |
| 108.445 | 201.41108Price 108.45248 | +85.7% |
Furthest below the fair value on each stock's page, updated every day.